Io Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Santa Ana CA United States (2010)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2011
NCT01540071
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Io Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

nrx194204 (3 trials)

Drugs in Phase 1 Trials (1)

erlotinib (tarceva) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Lung Neoplasms (Phase 1)

Parkinson Disease (Phase 1)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2